Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-110063 |
Brand: | MCE |
CAS: | 41270-96-6 |
MDL | MFCD00234609 |
---|---|
Molecular Weight | 282.08 |
Molecular Formula | C10H7IN2 |
SMILES | IC1=CC(C2=CC=CC=C2)=NC=N1 |
4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF) [1] .
MIF [1]
4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity
[1]
.
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes
[1]
.
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation
[1]
.
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner
[1]
.
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay [1]
Cell Line: | BMMs |
Concentration: | 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM |
Incubation Time: | 24 hours, 72 hours |
Result: | Inhibited osteoclastogenesis in a dose-dependent manner. |
Western Blot Analysis [1]
Cell Line: | BMMs |
Concentration: | 5 μM,10 μM, 20 μM |
Incubation Time: | 1 day, 3 days, 5 days |
Result: | Inhibited RANKL-induced osteoclast differentiation and bone resorption. |
4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | 8-weeks-old C57BL/6J male mice [1] |
Dosage: | 1 mg/kg, 5 mg/kg |
Administration: | Intraperitoneal injection; every 2 days; for 8 weeks |
Result: | Alleviated OVX-induced osteoporosis. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 250 mg/mL ( 886.27 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.5451 mL | 17.7255 mL | 35.4509 mL |
5 mM | 0.7090 mL | 3.5451 mL | 7.0902 mL |
10 mM | 0.3545 mL | 1.7725 mL | 3.5451 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.